

Scripps' 38th Annual Clinical Hematology & Oncology Conference • February 17-20, 2018

For more information visit www.scripps.org/hemonccme • Call: (858) 678-6400 • Email: med.edu@scrippshealth.org

Target Audience

- Hematologists/Oncologists
- Medical Oncologists
- Surgeons
- Radiation Oncologists
- Internists
- Pharmacists
- Nurse Practitioners
- Physician Assistants
- Nurses and others desiring an update in these specialty areas



Accreditation:

Physicians (MD, DO)

Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Scripps Health designates this live activity for a maximum of **25.25 AMA PRA Category 1 Credit(s)**™. Physicians should only claim credit commensurate with the extent of their participation in the activity

MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **25.25 MOC points** in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



Pharmacists

Approved by the California State Board of Pharmacy for pharmacist CE.



Scripps' 38th Annual Clinical Hematology & Oncology Conference

February 17-20, 2018
San Diego, California

Course Overview:

Scripps' 38th Annual Conference Clinical Hematology and Oncology Conference, is designed for hematologists, oncologists, surgeons, radiation oncologists, internists, and others desiring an update in these specialty areas. The primary objective of this course is to bring together clinicians and leading experts in diverse areas of hematology and oncology, affording them an intimate environment in which to discuss new clinical developments and significant advances.

The first day of the program will focus on nonmalignant hematology which will be followed by an update on hematologic malignancies on the second day. New developments in oncology with a focus on issues of current interest will be discussed on the third day, while the final day will review breast cancer innovations. All presenters will discuss their approaches to challenging but common clinical situations and there will be ample time for participant interaction.

Hyatt Regency La Jolla at Aventine

3777 La Jolla Village Drive
San Diego, CA 92122


Phone: (858) 552-1234

Reservations: (888) 421-1442

Website: <http://bit.ly/2jbEJqc>

Book your room today

Special rate of \$249 per night (plus taxes).
Visit conference website for full details.



Saturday, February 17, 2018 • Topic: Nonmalignant Hematology

6:30 a.m.	Breakfast Symposium hosted by Pfizer Expanded Indication for First-in-Class Oral Therapy for Treatment of a Broad Range of Women with HR+/HER2- Metastatic Breast Cancer Ann O'Dea—Kansas University TBD <i>A non-CME activity—RSVP online</i>
6:30 a.m.	Breakfast Symposium hosted by Exelixis CABOMETYX: Treatment of Patients with Advanced Renal Cell Carcinoma TBD <i>A non-CME activity—RSVP online</i>
7 a.m.	Registration, Breakfast & View Exhibits
7:50 a.m.	Welcome and Introduction
8 a.m.	ITP Update for 2018 John Kelton, MD—McMaster University
8:45 a.m.	'Mind the Gap': Timing Issues in Autoimmune HIT and Symmetrical Peripheral Gangrene Complicating DIC Theodore Warkentin, MD—McMaster University
9:30 a.m.	Break & View Exhibits
10 a.m.	Sickle Cell Disease and Other Hemoglobinopathies: 2018 Update Kathryn Hassell, MD—University of Colorado
10:45 a.m.	Hormones and Thrombosis: Everything the Hematologist Wants to Know Stephan Moll, MD—University of North Carolina, Chapel Hill
11:30 a.m.	Lessons Learned from Clinical Practice from Having Been an Expert Witness in Thrombosis & Hemostasis Law Suits Craig Kitchens, MD—University of Florida
12:15 p.m.	Lunch
1:15 p.m.	Radiological Pitfalls Relevant for the Practicing Heme-Onc Physician Katherine Birchard, MD—University of North Carolina, Chapel Hill,
2 p.m.	Oncology Drugs Causing Bleeding or Clotting David Garcia, MD—University of Washington
2:45 p.m.	Myelofibrosis: 2018 Review and Update Brandi Reeves, MD—University of North Carolina, Chapel Hill
3:30 p.m.	Break & View Exhibits
4 p.m.	Workshops Less Common Thromboses Stephan Moll, MD—University of North Carolina, Chapel Hill Syndromes of DIC Theodore Warkentin, MD—McMaster University Bleeding Disorders Not Due to Hemostatic Failure Craig Kitchens, MD—University of Florida Diagnosis & Management of Plasma Cell Disorders Morie Gertz, MD—Mayo Clinic Perplexing Patients with Thrombocytopenia John Kelton, MD—McMaster University
5 p.m.	Adjourn
5 p.m.	Welcome & Networking Reception
6 p.m.	Dinner Symposium hosted by Alexion Treatment of Paroxysmal Nocturnal Hemoglobinuria: A Life-Threatening, Complement-Mediated Disease Bradley H Lewis, MD—The Permanente Medical Group <i>A non-CME activity—RSVP online</i>

Monday, February 19, 2018 • Topic: Updates in Oncology

7 a.m.	Breakfast & View Exhibits
8 a.m.	CardioOncology, the Role of the Cardiologist in Modern Oncologic Care Jean-Bernard Durand, MD—University of Texas, MD Anderson
8:45 a.m.	Prostate Cancer 2018 David Quinn, MD—University of Southern California
9:30 a.m.	Break & View Exhibits
10 a.m.	Upfront Management of Operable Lung Cancer Antoinette Wozniak, MD—Barbara Ann Karmanos Cancer Institute
10:45 a.m.	Individualizing Therapy and Improving Survival in Colorectal Cancer Cathy Eng, MD—University of Texas, MD Anderson
11:30 a.m.	Immunotherapy in Upper Gastrointestinal Malignancies: Hepatocellular Carcinoma Anthony B. El-Khoueiry, MD—University of Southern California
12:15 p.m.	Lunch
1:15 p.m.	Incorporating Precision Medicine Into Your Practice: How, Why, and When? Edward Kim, MD—Levine Cancer Institute
2 p.m.	Operable Melanoma: Updates on Screening, Prognostication, and Adjuvant-Neoadjuvant Therapies Ahmad A. Tahrini, MD—Cleveland Clinic Taussig Cancer Institute
2:45 p.m.	Biomarkers for Immunotherapy: An Illusion or Reality? Leona Horn, MD—Vanderbilt University Medical Center
3:30 p.m.	Break & View Exhibits
4 p.m.	Important Issues Facing Oncologists, and What You Can Do Barbra McAnery, MD, President Elect—American Medical Association
 Dr. McAnery is a renowned board-certified medical oncologist/hematologist from Albuquerque, N.M., was elected president-elect of the American Medical Association in June 2017. Dr. McAnery has served on the AMA Board of Trustees since 2010, including as its chair in 2015–2016. An impressive leader, Dr. McAnery has been a member of the American Society of Clinical Oncology (ASCO) Board of Directors, president of the New Mexico Medical Society (NMMS), president of the Greater Albuquerque Medical Association, and president of the New Mexico Chapter of the American College of Physicians."	
4:45 p.m.	Targeted Therapy for Head and Neck Cancer Joshua Baum, MD—University of Pennsylvania
5:30 p.m.	Adjourn
6 p.m.	Dinner Symposium hosted by Astellas and Pfizer Oncology A Treatment Option for Patients Who Have Progressed to Metastatic Castration-Resistant Prostate Cancer (CRPC) Przemyslaw Twardowski, MD—City of Hope <i>A non-CME activity—RSVP online</i>

*Topics, times and speakers are subject to change

Sunday, February 18, 2018 • Topic: Malignant Hematology

6:30 a.m.	Breakfast Symposium hosted by AstraZeneca Immunotherapy for Patients With Locally Advanced, Unresectable Non-small Cell Lung Cancer Douglas Reznick, MD—Rocky Mountain Cancer Centers <i>A non-CME activity—RSVP online</i>
7 a.m.	Breakfast & View Exhibits
8 a.m.	Novel Strategies in Acute Leukemia of Relevance to Clinical Practice Hagop Kantarjian, MD—University of Texas, MD Anderson
8:45 a.m.	Complicated Clinical Scenarios in Myeloma Morie Gertz, MD—Mayo Clinic
9:30 a.m.	Break & View Exhibits
10 a.m.	CAR-T Therapy for Acute Leukemia Stephen Schuster, MD—University of Pennsylvania
10:45 a.m.	Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies James Mason, MD—Scripps Health
11:30 a.m.	Immunotherapy in Myeloid Malignancies Eunice Wang, MD—Roswell Park Cancer Institute
12:15 p.m.	Lunch
1:15 p.m.	The Oncology Care Model: Medicare's Alternative Payment Model and the Future of Bundled Payments in Oncology Stephen Grubbs, MD—American Society of Clinical Oncology
2 p.m.	CLL: Ibrutinib Alone or Ibrutinib "Plus"? Marin Xavier, MD—Scripps Health
2:45 p.m.	Evolution of Targeted Therapies for Myeloproliferative Neoplasms Brandi Reeves, MD—University of North Carolina, Chapel Hill
3:30 p.m.	Breakfast & View Exhibits
4 p.m.	Workshops (Repeat from Saturday) Less Common Thromboses Stephan Moll, MD—University of North Carolina School of Medicine Syndromes of DIC Theodore Warkentin, MD—McMaster University Bleeding Disorders Not Due to Hemostatic Failure Craig Kitchens, MD—University of Florida Diagnosis & Management of Plasma Cell Disorders Morie Gertz, MD—Mayo Clinic
5 p.m.	Adjourn

*Topics, times and speakers are subject to change

Tuesday, February 20, 2018 • Topic: Innovations in Breast Cancer

7 a.m.	Breakfast
7:30 a.m.	Lifestyle Interventions to Improve Cardiorespiratory Fitness and Reduce Breast Cancer Occurrence Kathryn Elizabeth Hudson, MD—Duke University
8:15 a.m.	The WISDOM Study: Screening for Breast Cancer Allison Stover—Athena Breast Health Network
9 a.m.	Break
9:15 a.m.	Management of Heterogeneous Breast Cancers Heather McArthur, MD, MPH—Cedars-Sinai
10 a.m.	Optimizing Neoadjuvant/Adjuvant Treatment Options in Patients With HER2 Amplification Sara Hurvitz, MD—University of California, Los Angeles
10:45 a.m.	The Triple Negative Conundrum Joyce O'Shaughnessy, MD—Baylor-Sammons Cancer Center
11:30 a.m.	Final Adjournment

*Topics, times and speakers are subject to change

	Rates	Thru Dec 31	Dec 31–Feb 11	On-site after Feb 11
Physicians (MD/DO)		\$640	\$690	\$715
Other Health Care Professionals (NP, PA, RN, PhD, PharmD, Etc.)		\$465	\$515	\$540
Fellows and Residents		\$190	\$240	\$265
Day Rate (1 Day)		\$290	\$340	\$365
Day Rate (2 Day)		\$540	\$640	\$690

To RSVP for symposiums please visit
www.scripps.org/HemOncCME